| Primary |
| Chronic Lymphocytic Leukaemia |
51.7% |
| Product Used For Unknown Indication |
12.9% |
| Premedication |
5.9% |
| Prophylaxis |
3.1% |
| B-cell Lymphoma |
2.5% |
| Drug Use For Unknown Indication |
2.5% |
| Hypertension |
2.5% |
| Diffuse Large B-cell Lymphoma Recurrent |
2.2% |
| Non-hodgkin's Lymphoma |
2.2% |
| Chronic Lymphocytic Leukaemia Refractory |
2.0% |
| Lymphoma |
1.7% |
| Hodgkin's Disease |
1.4% |
| Richter's Syndrome |
1.4% |
| Sinusitis |
1.4% |
| Asthma |
1.1% |
| Diffuse Large B-cell Lymphoma |
1.1% |
| Headache |
1.1% |
| Pneumonia |
1.1% |
| Supplementation Therapy |
1.1% |
| Allergy Prophylaxis |
0.8% |
|
| Neutropenia |
11.0% |
| Rash |
10.4% |
| Urticaria |
10.4% |
| Infusion Related Reaction |
8.5% |
| Pneumonia |
8.5% |
| Febrile Neutropenia |
5.5% |
| Death |
4.9% |
| Thrombocytopenia |
4.9% |
| Disease Progression |
4.3% |
| Pyrexia |
4.3% |
| Neuropathy Peripheral |
3.0% |
| Product Quality Issue |
3.0% |
| Sepsis |
3.0% |
| Weight Decreased |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Adverse Drug Reaction |
2.4% |
| Drug Ineffective |
2.4% |
| Nausea |
2.4% |
| Neutrophil Count Decreased |
2.4% |
| Off Label Use |
2.4% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
35.7% |
| B-cell Small Lymphocytic Lymphoma |
15.9% |
| Product Used For Unknown Indication |
11.1% |
| Non-hodgkin's Lymphoma |
8.7% |
| Diabetes Mellitus |
6.3% |
| Allergy Prophylaxis |
4.8% |
| Hypertension |
3.2% |
| Hypokalaemia |
3.2% |
| Prophylaxis |
3.2% |
| Waldenstrom's Macroglobulinaemia |
2.4% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Hypertriglyceridaemia |
1.6% |
| Antibiotic Prophylaxis |
0.8% |
| Pain |
0.8% |
| Prophylaxis Of Nausea And Vomiting |
0.8% |
|
| Staphylococcal Sepsis |
12.5% |
| Vomiting |
12.5% |
| Abdominal Pain Upper |
6.3% |
| Cognitive Disorder |
6.3% |
| Drug Ineffective |
6.3% |
| Haemolytic Anaemia |
6.3% |
| Pancreatitis Acute |
6.3% |
| Progressive Multifocal Leukoencephalopathy |
6.3% |
| Pseudomembranous Colitis |
6.3% |
| Urinary Retention |
6.3% |
| Chronic Lymphocytic Leukaemia |
3.1% |
| Disease Recurrence |
3.1% |
| Haemophilus Infection |
3.1% |
| Liver Disorder |
3.1% |
| Memory Impairment |
3.1% |
| Myelodysplastic Syndrome |
3.1% |
| Sepsis |
3.1% |
| Septic Shock |
3.1% |
|
| Concomitant |
| Drug Use For Unknown Indication |
32.0% |
| Chronic Lymphocytic Leukaemia |
24.0% |
| Product Used For Unknown Indication |
24.0% |
| B-cell Lymphoma |
16.0% |
| Chronic Lymphocytic Leukemia |
4.0% |
|
| Chronic Lymphocytic Leukaemia |
25.0% |
| Death |
25.0% |
| Disease Progression |
12.5% |
| Infection In An Immunocompromised Host |
12.5% |
| Pancytopenia |
12.5% |
| Sepsis |
12.5% |
|
